Head-to-head · WeighScore
FuturHealth vs TrueMe
The verdict
TrueMe takes it — 67.6/100 to 65.6/100, but only just.
TrueMe grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. TrueMe is a cash-pay telehealth brand offering compounded semaglutide and tirzepatide with added B vitamins, alongside NAD+, sermorelin and glutathione. FuturHealth is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | FuturHealth | TrueMe |
|---|---|---|
| WeighScore | 65.6/100 | 67.6/100 |
| Grade | C | C |
| Scorecard rank | #215 | #163 |
| Semaglutide | $199/mo (compounded) | $159/mo (compounded) |
| Tirzepatide | Not disclosed | $189/mo (compounded) |
| Coverage | Coverage not published | 6 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Injection only |
Graded #215 · C
Strengths
- LegitScript Certified and HITRUST Certified
- Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
- Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
- Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths
Where it loses points
- Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
- BBB complaints describe recurring charges without medication received — confirm cancellation flow first
- Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
- Pricing not shown until after the qualification questionnaire or portal login
- Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber
Graded #163 · C
Strengths
- One price covers consultation, medication, shipping, supplies and provider support, and the site states there are no separate membership fees
- Same price at every dose, so the cost does not climb as a provider titrates the dose upward
- Full pricing is published up front — no intake form is required before you can see what you will pay
- Carries a genuine LegitScript-issued seal (ID 50205625) that resolves on LegitScript's own asset host
- Names its telehealth platform (Telegra) and physician network (Strive), and the returns address names CarePoint Infusion Pharmacy in Stafford, Texas
Where it loses points
- Serves only six states (AZ, CO, MO, PA, TX, WI), far narrower coverage than most national GLP-1 telehealth
- Prices marketed per month are charged every 4 weeks at checkout — 13 charges a year, not 12
- You pay before completing the medical intake, and approval is not guaranteed at the moment you are charged
- The 3-month rates ($119 and $139/mo) are a single upfront charge of $357 or $417, not a lower monthly plan
- A Featured In strip shows CNN, Fox News, Forbes, New York Times and NPR logos with no linked coverage
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.